Our technology can save lives with early cancer detection
Cancer is one of the most common causes of death in the US, second only to cardiovascular diseases. Multi-cancer early detection is on the cutting edge of cancer research, promising to reduce cancer deaths by 40%.
Non-invasive multi-cancer early detection
miRoncol is developing a novel test, using well-established technology and infrastructure, that can detect multiple types of cancer in their early stages.
High accuracy
Compared to other multi-cancer early detection technologies, miRoncol's unique test demonstrates superior performance with high sensitivity and specificity.
High affordability
miRoncol provides a low-cost solution to cancer screening using an RT-PCR based assay of limited number of microRNAs.
High accessibility
miRoncol's test requires only a small blood sample, one that can be readily tested in any diagnostic lab across the US.
Scientifically-proven performance
12
types of cancer are currently supported, with more on the way.
>99%
Specificity, i.e. <1% of non-cancer samples would be tested as positive.
~90%
Sensitivity, i.e. ~90% of actual cancer cases can be detected.
11,000+
blood samples used for model development and validation.
Publications
At the 2021 World Conference on Lung Cancer, our study was not only selected for oral presentation, but also highlighted in the Meeting News.
​
Poster presentation at the 2022 Annual Meeting of American Association for Cancer Research.
​
